Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium

• Status: Recruiting
• Trial end date: 2022-03-30
• Target enrollment: 0
• Participant gender: Female

Summary

This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sara Rafael Fernandez
• Treatments: Mitogens

Criteria

Inclusion Criteria:

• Women who signed informed consent.

• Women who understand the Spanish language.

• Women under 42 years

Exclusion Criteria:

• Thrombopenia.

• Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.

• Ovarian tumors.

• Benign uterine tumors require surgical treatment

• Local acute inflammatory diseases

• Patients with malignant tumors requiring chemotherapy.

• Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.

• Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)